Inclusion Criteria:

          -  Documented histological or cytological diagnosis of renal cell carcinoma with a
             clear-cell component

          -  Adult patients

          -  Karnofsky Performance Score (KPS) ≥ 70%

          -  Measurable Disease per RECIST 1.1

          -  1-2 lines of prior therapy for advanced or metastatic RCC including at least one
             antiangiogenic therapy or nivolumab + ipilimumab

          -  Adequate hepatic, renal, cardiac and hematologic function

        Exclusion Criteria:

          -  Prior treatment with cabozantinib (or other MET inhibitor) or CB-839

          -  Receipt of other anticancer therapy within 2 - 6 weeks, depending on the treatment

          -  Untreated or active brain metastases or central nervous system cancer, as defined per
             protocol

          -  Prior gastric surgery, small bowel resection, or other conditions that may impede
             adequate absorption of oral study drug

          -  Known active infection with HIV, Hepatitis B or C virus

          -  Requirement for continued proton pump inhibitor after randomization